Arthur Roberts

Dr. Arthur Roberts


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
KLKaitlyn V. Ledwitch
Kaitlyn V. Ledwitch
MGMorgan E. Gibbs
Morgan E. Gibbs
RBRobert W. Barnes
Robert W. Barnes
ARArthur Roberts
Arthur Roberts

12 October 2011 in Biochemistry
Verified
Journal Article
Closed access
ARArthur Roberts
Arthur Roberts
JYJing Yang
Jing Yang
JHJames R. Halpert
James R. Halpert
SNSidney D. Nelson
Sidney D. Nelson
KTKenneth T. Thummel
Kenneth T. Thummel
WAWilliam M. Atkins
William M. Atkins


16 March 2016 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
KLKaitlyn V. Ledwitch
Kaitlyn V. Ledwitch
RBRobert Weldon Barnes
Robert Weldon Barnes
ARArthur Roberts
Arthur Roberts
Drug–drug interactions (DDIs) and associated toxicity from cardiovascular drugs represents a major problem for effective co-administration of cardiovascular therapeutics. A significant amount of drug toxicity from DDIs occurs because of drug interactions and multiple cardiovascular drug binding to the efflux transporter P-glycoprotein (Pgp), which is particularly problematic for cardiovascular drugs because of their relatively low therapeutic indexes. The calcium channel antagonist, verapamil and the cardiac glycoside, digoxin, exhibit DDIs with Pgp through non-competitive inhibition of digoxin transport, which leads to elevated digoxin plasma concentrations and digoxin toxicity. In the present study, verapamil-induced ATPase activation kinetics were biphasic implying at least two verapamil-binding sites on Pgp, whereas monophasic digoxin activation of Pgp-coupled ATPase kinetics suggested a single digoxin-binding site. Using intrinsic protein fluorescence and the saturation transfer double difference (STDD) NMR techniques to probe drug–Pgp interactions, verapamil was found to have little effect on digoxin–Pgp interactions at low concentrations of verapamil, which is consistent with simultaneous binding of the drugs and non-competitive inhibition. Higher concentrations of verapamil caused significant disruption of digoxin–Pgp interactions that suggested overlapping and competing drug-binding sites. These interactions correlated to drug-induced conformational changes deduced from acrylamide quenching of Pgp tryptophan fluorescence. Also, Pgp-coupled ATPase activity kinetics measured with a range of verapamil and digoxin concentrations fit well to a DDI model encompassing non-competitive and competitive inhibition of digoxin by verapamil. The results and previous transport studies were combined into a comprehensive model of verapamil–digoxin DDIs encompassing drug binding, ATP hydrolysis, transport and conformational changes.

27 December 2016 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
KLKaitlyn V. Ledwitch
Kaitlyn V. Ledwitch
ARArthur Roberts
Arthur Roberts

1 September 2018 in Clinical Pharmacology: Advances and Applications
Verified
Journal Article
Open access
PDF file
ARArthur Roberts
Arthur Roberts
MGMorgan E Gibbs
Morgan E Gibbs
As a result of an increasing aging population, the number of individuals taking multiple medications simultaneously has grown considerably. For these individuals, taking multiple medications has increased the risk of undesirable drug–drug interactions (DDIs), which can cause serious and debilitating adverse drug reactions (ADRs). A comprehensive understanding of DDIs is needed to combat these deleterious outcomes. This review provides a synopsis of the pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms that underlie DDIs. PK-mediated DDIs affect all aspects of drug disposition: absorption, distribution, metabolism and excretion (ADME). In this review, the cells that play a major role in ADME and have been investigated for DDIs are discussed. Key examples of drug metabolizing enzymes and drug transporters that are involved in DDIs and found in these cells are described. The effect of inhibiting or inducing these proteins through DDIs on the PK parameters is also reviewed. Despite most DDI studies being focused on the PK effects, DDIs through PD can also lead to significant and harmful effects. Therefore, this review outlines specific examples and describes the additive, synergistic and antagonistic mechanisms of PD-mediated DDIs. The effects DDIs on the maximum PD response (Emax) and the drug dose or concentration (EDEC50) that lead to 50% of Emax are also examined. Significant gaps in our understanding of DDIs remain, so innovative and emerging approaches are critical for overcoming them.